SRR1500428
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.337
- KRAS_SIGNALING_DN+0.329
- INFLAMMATORY_RESPONSE+0.275
- HEDGEHOG_SIGNALING+0.272
- BILE_ACID_METABOLISM+0.269
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.231
- COAGULATION+0.215
- IL6_JAK_STAT3_SIGNALING+0.207
- PANCREAS_BETA_CELLS+0.201
- MYOGENESIS+0.192
Top 10 suppressed
- MYC_TARGETS_V1-0.612
- MYC_TARGETS_V2-0.610
- UNFOLDED_PROTEIN_RESPONSE-0.503
- DNA_REPAIR-0.502
- G2M_CHECKPOINT-0.497
- E2F_TARGETS-0.485
- OXIDATIVE_PHOSPHORYLATION-0.464
- PI3K_AKT_MTOR_SIGNALING-0.409
- PROTEIN_SECRETION-0.392
- MTORC1_SIGNALING-0.376
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1340202 | GTEX | — | 0.936 |
| 2 | sclcMAD11162_S44.txt | — | cohortA1 | 0.933 |
| 3 | SRR1338627 | GTEX | — | 0.933 |
| 4 | SRR1330061 | GTEX | — | 0.926 |
| 5 | SRR1467011 | GTEX | — | 0.923 |
| 6 | MNG298 | — | — | 0.922 |
| 7 | SRR1415732 | GTEX | — | 0.918 |
| 8 | SRR1486863 | GTEX | — | 0.916 |
| 9 | SRR1336292 | GTEX | — | 0.916 |
| 10 | SRR1329761 | GTEX | — | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.337 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.329 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.275 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.272 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.269 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.231 | Inavolisib | — uncovered |
| COAGULATION | 0.215 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.207 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.201 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.192 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.187 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.186 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.178 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.175 | Inavolisib | — uncovered |
| HYPOXIA | 0.122 | Idelalisib | — uncovered |
| COMPLEMENT | 0.112 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.045 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.035 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.035 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.032 | Remibrutinib | — uncovered |